11 min.
Oncology treatment has come a long way. Prof. Dimitrios Kontoyiannis first discusses the recent changes in oncology treatment and their respective impact on the risk of invasive fungal infections. Then he adresses which emerging patient populations in the (hemato-)oncology setting are at an increased risk of infections. How do we properly identify them and what are the challenges in treatment of these patients?
This editorially independent interview has been financially sponsored by Gilead.